Who should be tested in low-prevalence countries?
Dyspepsia pathways differ. Guidelines, not blogs, set the default.
Resistance to common eradication drugs is rising in some regions. That is why regimens are not copied here — they change and they are clinical.
Whether mass screen-and-treat lowers gastric cancer enough to justify costs is a live East Asian policy debate.
Open questions
How do we keep eradication working?
Stewardship and local resistance maps matter. Recipes are omitted here.
Does treating everyone cut cancer enough?
Models and trials in East Asia are watched. Answers are policy-scale.
What is the role of CagA-negative strains?
Risk is not uniform. Strain talk belongs in research and specialist care.
Can we vaccinate?
Vaccine research exists. No routine global shot is standard as of the mid-2020s.
The frontier is smarter testing, not backyard isolates.
Keep exploring
More in Encounters
Influenza
A winter respiratory virus of drift and rare shift — surveillance and vaccines, not a cartoon villain.
Familiarity 93Tuberculosis
An airborne bacillus of latency and long care — programmes and air, not a drug recipe.
Familiarity 70Escherichia coli
Usually a gut resident; a minority of STEC pathotypes drive foodborne headlines.
Familiarity 82Staphylococcus aureus
A common skin neighbor and a resistance story called MRSA — not scare porn.
Familiarity 78Norovirus
A very-low-dose gut virus of schools and ships — soap and bleach surfaces, not alcohol-gel faith.
Familiarity 80